Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease

American Journal of Clinical Nutrition

Volumn 97, Issue 5, 2013, Pages 1004-1013

  Suzuki, Masahiko ^a   Yoshioka, Masayuki ^a   Hashimoto, Masaya ^a   Murakami, Maiko ^a   Noya, Miki ^a,b   Takahashi, Daisuke ^b   Urashima, Mitsuyoshi ^b  

^a Jikei University Katsushika Medical Center   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; COLECALCIFEROL; LEVODOPA; PLACEBO; VITAMIN D RECEPTOR;

ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PATIENT COMPLIANCE; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT; VITAMIN BLOOD LEVEL;

AGED; BLOOD PRESSURE; BODY MASS INDEX; CALCIUM, DIETARY; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PARKINSON DISEASE; QUESTIONNAIRES; RECEPTORS, CALCITRIOL;

EID: 84876909784     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.112.051664     Document Type: Article

References (33)

1. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients. Mov Disord 2005;20:1598-603.
2. Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V. Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 2008;65:1348-52.
3. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
4. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R, Wong JB, Egli A, Kiel DP, Henschkowski J. Fall prevention with supplemental and active forms of vitamin D: a metaanalysis of randomised controlled trials. BMJ 2009;339:b3692.
5. van den Bos F, Speelman AD, Samson M, Munneke M, Bloem BR, Verhaar HJ. Parkinson's disease and osteoporosis. Age Ageing (Epub ahead of print 6 November 2012).
6. Cole MH, Silburn PA, Wood JM, Worringham CJ, Kerr GK. Falls in Parkinson's disease: kinematic evidence for impaired head and trunk control. Mov Disord 2010;25:2369-78.
7. Dennison EM, Compston JE, Flahive J, Siris ES, Gehlbach SH, Adachi JD, Boonen S, Chapurlat R, Díez-Pérez A, Anderson FA Jr., et al. Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 2012; 50:1288-93.
8. Vaserman N. Parkinson's disease and osteoporosis. Joint Bone Spine 2005;72:484-8.
9. Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Saaksjarvi K, Heliovaara M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol 2010;67:808-11.
10. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology 1997;49:1273-8.
11. Suzuki M, Yoshioka M, Hashimoto M, Murakami M, Kawasaki K, Noya M, Takahashi D, Urashima M. 25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of PD. Mov Disord 2012; 27:264-71.
12. Lux WE, Kurtzke JF. Is Parkinson's disease acquired? Evidence from a geographic comparison with multiple sclerosis. Neurology 1987;37: 467-71.
13. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005;29:21-30.
14. Burne TH, McGrath JJ, Eyles DW, Mackay-Sim A. Behavioural characterization of vitamin D receptor knockout mice. Behav Brain Res 2005;157:299-308.
15. Butler MW, Burt A, Edwards TL, Zuchner S, Scott WK, Martin ER, Vance JM, Wang L. Vitamin D receptor gene as a candidate gene for Parkinson disease. Ann Hum Genet 2011;75:201-10.
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
17. Osaki Y, Morita Y, Fukumoto M, Akagi N, Yoshida S, Doi Y. Threedimensional stereotactic surface projection SPECT analysis in Parkinson's disease with and without dementia. Mov Disord 2005;20: 999-1005.
18. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006; 84:18-28.
19. (Published erratum appears in Am J Clin Nutr 2006;84:1253.)
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
21. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, et al. Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Stage (MDS-UPDRS): stage presentation and clinimetric testing results. Mov Disord 2008;23:2129-70.
22. Ideno Y, Takayama M, Hayashi K, Takagi H, Sugai Y. Evaluation of a Japanese version of the Mini-Mental State Examination in elderly persons. Geriatr Gerontol Int 2012;12:310-6.
23. Kohmoto J, Ohbu S, Nagaoka M, Suzukamo Y, Kihira T, Mizuno Y, Ito YM, Hith M, Yamaguchi T, Ohashi Y, et al. [Validation of the Japanese version of the Parkinson's Disease Questionnaire]. Rinsho Shinkeigaku 2003;43:71-6 (in Japanese).
24. Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, Hamashima C, Hisashige A, Tamura M. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002;11:341-53.
25. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in PD. Mov Disord 2010;25:2649-53.
26. Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL. Determination of vitamin D status by radioimmunoassay with an 125Ilabeled tracer. Clin Chem 1993;39:529-33.
27. Wang D, Clayton T, Bakhai A. Interaction. In: Wang D, Bakhai A, eds. Clinical trials. 1st ed. Oxford, United Kingdom: Remedica, 2006:305-16.
28. Muir SW, Montero-Odasso M. Effect of vitamin D supplementation on muscle strength, gait and balance in older adults: a systematic review and meta-analysis. J Am Geriatr Soc 2011;59:2291-300.
29. National Center for Biotechnology Information. Search for SNP on NCBI Reference Assembly. Available from: http://www.ncbi.nlm.nih. gov/projects/SNP/snp-ref.cgi?rs=2228570 (cited 10 November 2012).
30. Gross C, Eccleshall TR, Malloy PJ, Villa ML, Marcus R, Feldman D. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J Bone Miner Res 1996; 11:1850-5.
31. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL, Ma J. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007;4:e103.
32. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, Packe GE, Moore-Gillon JC, Darmalingam M, Davidson RN, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011;377:242-50.
33. Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, Vuillaume I, Corvol JC, Brefel-Courbon C, Ory-Magne F, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012;11: 589-96.